How much rapamycin, how often, for how long? A practical 2026 walk-through of the dosing protocols longevity physicians actually use, the trade-offs of each, and how to access the drug off-label.
Rapamycin is the most rigorously validated lifespan-extending drug in animal models. The Interventions Testing Program — a federally funded multi-site protocol that has tested dozens of compounds in genetically heterogeneous mice — has now reproduced rapamycin's lifespan benefit across more than a dozen independent cohorts. No other intervention has come close to that level of replication.
The translation question for humans is no longer "does rapamycin do something interesting at the cellular level?" It does. The questions are practical: at what dose, at what interval, for how long, and with what monitoring. This article summarizes the 2026 state of dosing thinking among the longevity physicians actively prescribing rapamycin off-label, what the human evidence supports, and how patients are obtaining it.
Rapamycin in transplant medicine is dosed daily to maintain trough drug levels that suppress the immune system. That dosing schedule produces well-known side effects — mouth ulcers, hyperlipidemia, glucose intolerance, immunosuppression — and is unsuitable for healthy people seeking healthspan benefits.
The longevity protocol is fundamentally different. It uses intermittent (pulse) dosing — a single oral dose every 7 to 14 days — designed to inhibit mTORC1 (the growth-and-storage complex) without persistently inhibiting mTORC2 (the metabolism-and-glucose complex). Pulse dosing in mice extends lifespan with substantially fewer metabolic side effects than continuous dosing. The clinical observation in humans, while not from randomized longevity outcome trials, is consistent: people on weekly or biweekly pulses tolerate the drug well and rarely report the immunosuppression-related issues seen in transplant patients.
The most common starting protocol. A single 5 mg oral dose taken on the same day each week, fasted (or with a small fat-containing snack to enhance absorption — about 35% bioavailability). This is the protocol used in the PEARL trial, the largest randomized human study of rapamycin for healthspan to date, and the dose most commonly prescribed by physicians in the longevity space who report on their practice.